According to the Centers for Medicare and Medicaid Services, Gitlow has received more than US $65,000 in funding since 2013. This includes more than US $16,000 in consulting payments from Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. He has also received more than $43,000 in fees for consulting with multiple pharmaceutical firms including Kaleo, Inc, makers of the opioid overdose antidote Evzio (Naloxone HCl injection); Reckitt Benckiser, makers of Suboxone; and Orexo, makers of the opioid products Abstral (Fentanyl) and Zubsolv (Buprenorphine/naloxone).